Table 2 Large, recent studies of ECMO for acute respiratory failure: Key pre-ECMO data and outcomes

Peek, ECMO Arm, CESAR trial [18]

76 ± 29

7.1 ± 0.1

–

14 ± 9

3.5 ± 0.6

36 (17–104)

–

10 (5–23)

–

0

33 (37%)

Schmidt [50]

59 (48–75)

7.25 (7.15–7.35)

36 (31–43)^*

13 (10–16)

–

57 (19–151)

30

7 (4–13)

–

–

1,017 (43%)

Brogan [26]

57 (45–71)

7.27 (7.18–7.36)

40 (35–48)^*

13 (10–16)

–

52 (20–160)

–

23 ± 20

30

4

732 (50%)

Enger [51]

69 (65–74)^†

7.22 (7.22–7.25)^†

35 (34–36)^*†

16 (16–17)^†

3.5 (3.4–3.5)^†

120 (96–168)^†

–

10 (9–11)^†

–

–

117 (41%)

Hemmila [27]

55 ± 16

7.31 ± 0.12

44 ± 11^*

13 ± 5

–

96 ± 72

–

9 ± 8

–

3

123 (48%)

Schmid [32]

77 ± 47

7.2 ± 0.2

35 ± 6^*

18 ± 6

3.4 ± 0.5

144 ± 240

–

12 ± 9

–

–

78 (44%)

Schmidt [33]

53(43–60)

7.22(7.15–7.32)

32 (30–35)

10 (8–12)

–

120 (24–264)

94

15 (8–30)

46

3

50 (36%)

Lindskov [31]

48 (37–60)

7.26 ± 0.15

37 (35–41)

–

–

–

–

9 (1–23)

–

9

36 (29%)

Roch [49]

60 (50–70)

7.1 ± 0.2

32 (29–35)

–

3.5 (3.3–3.7)

48 (24– 194)

85

9 (7–13)

29

2

48 (56%)

Rega [74]

56 ± 18

7.22 ± 0.18

44 ± 11^*

13 ± 3

–

108 ± 178

–

7 ± 5

20

–

40 (57%)

Mols [28]

96 ± 51

7.30 (7.22–7.40)

–

–

3.2 ± 0.4

–

–

12 ± 7

7

2

28 (45%)

Muller [35]

64 (48–86)

7.20 (7.13–7.30)

36 (32–40)^*

16 (13–20)

3.6 (3.3–3.8)

1.0 (1.0–4.8)

–

9 (5–13)

30

–

33 (55%)

Lewandowski [29]

–

7.32 ± 0.10

39 ± 7^*

12 ± 3

3.4 ± 0.2

312 ± 216

–

23 ± 17

–

–

22 (45%)

Forrest [34]

57 (47–65)

7.20 (7.13–7.3)

–

16 (12–18)

3.7 (3.5–3.7)

48 (24–48)

34

10 (7–17)

37

3

5 (13%)

Frenckner [75]

47 (31–65)

–

41 (29–54)^*

13 (0–20)

3.5 (3.0–4.0)

120 (24–672)

100

17 (2–57)

16

8

13 (34%)

Michaels [46]

52 ± 3

–

–

–

–

68 ± 9

–

7 ± 1

–

6

15 (40%)

Beiderlinden [30]

63 ± 28

7.1 ± 0.2

–

19 ± 3

3.8 ± 0.3

132 ± 168

–

10 (7–15)

–

–

15 (47%)